Literature DB >> 11121861

Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.

I Ohta1, I Gorai, Y Miyamoto, J Yang, J H Zheng, N Kawata, F Hirahara, S Shirotake.   

Abstract

Chemosensitivity to the drugs plays a crucial role in the treatment of ovarian cancer. In this study, we evaluate the cytotoxicity of chemotherapeutic agents in six ovarian cancer cell lines; four clear cell adenocarcinoma and two serous papillary adenocarcinoma, using seven single drugs and seven sets of drug combinations with tetrazolium-based semiautomated colorimetric (MTT) assay. The drug concentration which produced 50% growth inhibition (IC50) of cisplatin was within clinically achievable range in five cell lines. The area under the curve (AUC) at IC50 of cyclophosphamide was below the clinically achievable AUC in two serous papillary cell lines. Paclitaxel was more effective in clear cells than serous papillary cells. The intensification of cytotoxicity was observed in the combinations of paclitaxel and cisplatin, and cyclophosphamide and cisplatin or 5-fluorouracil irrespective of histopathological characteristics of the original tumor. Our results indicate that ovarian cancer cell lines respond to chemotherapeutic agents heterogeneously depending upon histopathological features, indicating individualized regimens may improve survival in ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11121861     DOI: 10.1016/s0304-3835(00)00605-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy.

Authors:  Shinji Kurosaka; Akira Irie; Hideyuki Mizoguchi; Norihiko Okuno; Keiichi Iwabuchi; Shiro Baba
Journal:  Int J Clin Oncol       Date:  2005-10       Impact factor: 3.402

2.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

3.  Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.

Authors:  Satoko Yamaguchi; Yoshiko Maida; Mami Yasukawa; Tomoyasu Kato; Masayuki Yoshida; Kenkichi Masutomi
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.

Authors:  Hiroaki Itamochi; Junzo Kigawa; Habiba Sultana; Takahiro Iba; Ryoji Akeshima; Shunji Kamazawa; Yasunobu Kanamori; Naoki Terakawa
Journal:  Jpn J Cancer Res       Date:  2002-06

5.  Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Authors:  Miriam Franklin; Lucy Gentles; Elizabeth Matheson; Nick Bown; Paul Cross; Angela Ralte; Connor Gilkes-Immeson; Alice Bradbury; Maryam Zanjirband; John Lunec; Yvette Drew; Rachel O'Donnell; Nicola J Curtin
Journal:  Cancer Med       Date:  2018-08-14       Impact factor: 4.452

Review 6.  The Endometriotic Tumor Microenvironment in Ovarian Cancer.

Authors:  Jillian R Hufgard Wendel; Xiyin Wang; Shannon M Hawkins
Journal:  Cancers (Basel)       Date:  2018-08-07       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.